TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17571831

Group type: EXPERIMENTAL
Intervention: Perforated, stretchable cloth tape (Hypafix)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Elastic spica bandage
Number of subjects: 294
Study: 15057739

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 2 x 400 mg/day + Metronidazole (MET) 2 x 500 mg/day
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) + Metronidazole (MET)
Number of subjects: 114
Study: 11182039

Group type: EXPERIMENTAL
Intervention: Doxifluridine 600 mg/body/day (group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Doxifluridine 800 mg/body/day (group B)
Number of subjects: 37
Study: 9270458

Group type: EXPERIMENTAL
Intervention: 10 day prescription of antibiotics
Number of subjects: 716

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 716

Group type: COMPARATOR
Intervention: Delayed prescription if sore throat had not started to settle after three days
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed for sore throat during the previous year
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Longer duration of illness (> 5 days)
Number of subjects: 716

Group type: COMPARATOR
Intervention: No antibiotics or delayed prescription
Number of subjects: 716
Study: 8173754

Group type: EXPERIMENTAL
Intervention: WEB 2086 40 mg three times daily for 12 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: COMPARATOR
Intervention: WEB 2086 and Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: WEB 2086
Number of subjects: 106
Study: 2906380

Group type: EXPERIMENTAL
Intervention: Sydnocarb (10 mg X 2 in air or 30 mg X 5 in water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sydnogluton (sydnocarb 30 mg + glutamic acid 0.25 g X 5 in cold water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2179222

Group type: EXPERIMENTAL
Intervention: Sildimac (new drug delivery system for silver sulfadiazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silvadene cream 1% (twice-daily wound cleansing)
Number of subjects: 0
Study: 1235149

Group type: EXPERIMENTAL
Intervention: Isokinetic high speed contraction
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isokinetic low speed contraction
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isotonic
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 31338676

Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation
Number of subjects: 0
Study: 28159782

Group type: EXPERIMENTAL
Intervention: Tenapanor (3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 26115513

Group type: EXPERIMENTAL
Intervention: sertraline plus mirtazapine
Number of subjects: 36

Group type: COMPARATOR
Intervention: sertraline plus placebo
Number of subjects: 36
Study: 24176228

Group type: EXPERIMENTAL
Intervention: Baobab fruit extract (18.5 g and 37 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baobab fruit extract (1.88% added to white bread)
Number of subjects: 0
Study: 20804437

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Topical treatment
Number of subjects: 128
Study: 19406374

Group type: EXPERIMENTAL
Intervention: High body shape concern group (n=23)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low body shape concern group (n=19)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 17320021

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulators (SERMs) such as raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 15036783

Group type: EXPERIMENTAL
Intervention: Pure carbohydrates
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pure protein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pure fat
Number of subjects: 15
Study: 11192308

Group type: EXPERIMENTAL
Intervention: Leucocyte‐depletion filters added to the CPB circuit (treatment group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard CPB without leucocyte‐depletion filters (control group)
Number of subjects: 20
Study: 9203879

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vecuronium 100 micrograms.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 90
Study: 7953209

Group type: EXPERIMENTAL
Intervention: Experimental units (E) received feedback on the first measurement and one unit received special intervention concerning documentation.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control units (C) did not receive feedback or special intervention.
Number of subjects: 120
Study: 3314798

Group type: EXPERIMENTAL
Intervention: Acifran 100 mg t.i.d.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acifran 300 mg t.i.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30476108

Group type: EXPERIMENTAL
Intervention: Isavuconazole (200 mg) administered three times daily for 2 days, then once daily.
Number of subjects: 160
Study: 27312961

Group type: EXPERIMENTAL
Intervention: Home modifications (e.g., handrails, grab rails, outside lighting, edging for outside steps, slip-resistant surfacing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home modifications
Number of subjects: 0
Study: 27097430

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine hemorrhoids lotion for fumigation
Number of subjects: 348

Group type: COMPARATOR
Intervention: 1 000 mL 1: 5 000 potassium permanganate solution for sitz bath
Number of subjects: 348
Study: 23380913

Group type: EXPERIMENTAL
Intervention: 0.4 mg folic acid
Number of subjects: 2508

Group type: EXPERIMENTAL
Intervention: 4 mg folic acid
Number of subjects: 2508

Group type: EXPERIMENTAL
Intervention: Combined folic acid groups (0.4 mg and 4 mg)
Number of subjects: 2508
Study: 21153694

Group type: EXPERIMENTAL
Intervention: Group A (3-sessions)
Number of subjects: 6987

Group type: COMPARATOR
Intervention: Group B (1-session)
Number of subjects: 6987

Group type: EXPERIMENTAL
Intervention: Group A (3-sessions) completers
Number of subjects: 6987
Study: 18030540

Group type: EXPERIMENTAL
Intervention: Peer coach support (N = 70)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Brochure support (N = 66)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Peer coach support for patients needing no support (N = 49)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Patients who declined support (N = 41)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Patients who could not be contacted (N = 49)
Number of subjects: 275
Study: 16534471

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) immune globulin
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 146
Study: 14652439

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg Q6H
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 10224639

Group type: EXPERIMENTAL
Intervention: Self-management therapy with choice of target (behavioral or cognitive)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-management therapy without choice of target
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-management therapy with choice of target
Number of subjects: 40
Study: 9085491

Group type: EXPERIMENTAL
Intervention: 5 mg dose of ritanserin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1813200

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% Triclosan and 2.0% copolymer)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 121
Study: 6401550

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment with niridazole 25 mg/kg and metrifonate 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrifonate 10 mg/kg
Number of subjects: 0
Study: 29488121

Group type: EXPERIMENTAL
Intervention: PACX (paclitaxel/capecitabine)
Number of subjects: 320

Group type: COMPARATOR
Intervention: XP (cisplatin/capecitabine)
Number of subjects: 320
Study: 26856191

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) inhalation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isotonic saline (IS) inhalation
Number of subjects: 21
Study: 24145220

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22530354

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week) + Teriparatide (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etanercept (50 mg/week)
Number of subjects: 20
Study: 21092228

Group type: EXPERIMENTAL
Intervention: High-energy diet + exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, high protein diet + exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Low carbohydrate, moderate protein diet + exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: High carbohydrate, low protein diet + exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: No diet + exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Caloric restriction + exercise (all groups)
Number of subjects: 141

Group type: COMPARATOR
Intervention: No diet + no exercise control group (CON)
Number of subjects: 141

Group type: COMPARATOR
Intervention: No diet + exercise control (ND)
Number of subjects: 141
Study: 18502991

Group type: EXPERIMENTAL
Intervention: Timolol-dorzolamide fixed combination (TDFC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Timolol-dorzolamide fixed combination (TDFC) and Latanoprost 0.005%
Number of subjects: 27
Study: 15933983

Group type: EXPERIMENTAL
Intervention: Adjustable valvulotome
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed valvulotome
Number of subjects: 30
Study: 12913687

Group type: EXPERIMENTAL
Intervention: Active warming of the abdomen and lower back region (42C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No warming
Number of subjects: 100
Study: 10215732

Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg b.d., amoxycillin 500 mg b.d., clarithromycin 400 mg b.d. for 7 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LACP (LAC regimen plus polaprezinc 150 mg b.d. for 7 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: LAC (lansoprazole, amoxycillin, clarithromycin)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LACP (LAC plus polaprezinc)
Number of subjects: 66
Study: 7869193

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children with NF‐1 and OPTs
Number of subjects: 219

Group type: COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children without OPTs (control group)
Number of subjects: 219
Study: 1694235

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy regimens (MOPP/ABVD; CAD plus MOPP plus ABV) combined with intermediate-dose radiation therapy (RT)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Patients with two or more unfavorable characteristics
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Patients with none or only one unfavorable factor
Number of subjects: 185
Study: 621612

Group type: EXPERIMENTAL
Intervention: Chlorambucil stable dose (0.2 mg/kg/day) for 56 to 60 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chlorambucil increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/m2 on alternate days)
Number of subjects: 21
Study: 29927884

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives (HC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Never used hormonal contraceptives (NHC)
Number of subjects: 18
Study: 30422390

Group type: EXPERIMENTAL
Intervention: Praliciguat (15/30 mg, 20/40 mg, 30/40 mg, and weight-based)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Praliciguat
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 28695804

Group type: EXPERIMENTAL
Intervention: Regular Tai Chi exercise (group B)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Calcium 600 mg/d + VitD3 800 U/d (group C)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Calcium 600 mg/d + 25 hydroxyl vitamin D (25OHD) 0.25 μg/d (group D)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 614
Study: 26679652

Group type: EXPERIMENTAL
Intervention: 5.0 g sucrose gel
Number of subjects: 533

Group type: COMPARATOR
Intervention: 5.0 g metronidazole gel
Number of subjects: 533
Study: 23389750

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control ITP patients
Number of subjects: 22
Study: 21695906

Group type: EXPERIMENTAL
Intervention: sports intervention
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: diet intervention
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: sports and diet intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: control group
Number of subjects: 232
Study: 19091346

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for at least 30 days before surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17407636

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily (BID)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 377
Study: 15379878

Group type: EXPERIMENTAL
Intervention: Blue light irradiation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (non-irradiation side)
Number of subjects: 31
Study: 11172832

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily for 7 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9645591

Group type: EXPERIMENTAL
Intervention: Low dose inhaled fluticasone propionate (250 microg b.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 23
Study: 8942333

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 during desflurane anaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 during isoflurane anaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium during desflurane anaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium during isoflurane anaesthesia
Number of subjects: 0
Study: 2332814

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 518290

Group type: EXPERIMENTAL
Intervention: Weekend workshops on sex education
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-program control group
Number of subjects: 0
Study: 30243853

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU twice daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 28107408

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation with 8 cmH2O PEEP (PEEP group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low tidal volume ventilation without PEEP (ZEEP group)
Number of subjects: 38
Study: 24725075

Group type: EXPERIMENTAL
Intervention: tDCS intervention with 10 consecutive sessions, allowing for 2 nonconsecutive missed visits
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS intervention with 10 consecutive sessions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS intervention
Number of subjects: 120
Study: 22701297

Group type: EXPERIMENTAL
Intervention: LCR35 at least 108 CFU/day (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LCR35 at 2 × 108 CFU/day (group 2)
Number of subjects: 20
Study: 20844187

Group type: EXPERIMENTAL
Intervention: Dietary counseling provided for mothers during 10 home visits in the first year of life
Number of subjects: 500
Study: 18378374

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (on)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (off)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time reproduction task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Warned reaction time task
Number of subjects: 12
Study: 16706961

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (target INR 1.5-2.0)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Elevated D-dimer
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Elevated FVIIIc
Number of subjects: 508

Group type: COMPARATOR
Intervention: One prior VTE on placebo
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: More than one prior VTE
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: One prior VTE
Number of subjects: 508
Study: 12905053

Group type: EXPERIMENTAL
Intervention: 250 mg Solu‐Medrol intravenously and 160 mg Depo‐Medrol intramuscularly, plus 80 mg Depo‐Medrol on the dural sac
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sodium chloride instead of Depo‐Medrol
Number of subjects: 80
Study: 10977010

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation after 3 months of metformin therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 7488478

Group type: EXPERIMENTAL
Intervention: Wound infiltration with ketorolac 30 mg in saline
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wound infiltration with ketorolac 30 mg with 0.25% bupivacaine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wound infiltration with 0.25% bupivacaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (ketorolac 60 mg i.m.)
Number of subjects: 32
Study: 2285455

Group type: EXPERIMENTAL
Intervention: Educational session consisting of a 40-minute session with a 10-minute video presentation and discussion by the teacher on BP.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-minute videotape and complementary print program guide.
Number of subjects: 0
Study: 6118830

Group type: EXPERIMENTAL
Intervention: 1.5 mg bromazepam
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 3.0 mg bromazepam
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31154292

Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 350

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 350
Study: 28403335

Group type: EXPERIMENTAL
Intervention: Needle (G3)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Seed (G2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (G1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tape (G4)
Number of subjects: 180
Study: 26459358

Group type: EXPERIMENTAL
Intervention: FES treatment group (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 32
Study: 24261693

Group type: EXPERIMENTAL
Intervention: Blunt abdominal entry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exteriorisation of the uterus for repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single layer closure of the uterus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromic catgut for uterine repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's health outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent pregnancy outcomes
Number of subjects: 0
Study: 21496936

Group type: EXPERIMENTAL
Intervention: Group MVB: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg), vitamin B1 (10 mg), B2 (10 mg), B6 (10 mg), biotin (200 μg), B12 (10 μg), folic acid (1 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group MV: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Group P: placebo
Number of subjects: 75
Study: 19969161

Group type: EXPERIMENTAL
Intervention: Action Coping Planning (ACP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Action Planning Only (APO)
Number of subjects: 44
Study: 17718106

Group type: EXPERIMENTAL
Intervention: Zileuton CR, 1,200 mg twice daily
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo CR, twice daily
Number of subjects: 613
Study: 15028073

Group type: EXPERIMENTAL
Intervention: IVF group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Disopyramide (300 mg/day)
Number of subjects: 9
Study: 11440290

Group type: EXPERIMENTAL
Intervention: Topical 0.5% fluorouracil once daily for up to 28 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Topical 5% fluorouracil twice daily for up to 28 days
Number of subjects: 21
Study: 9505769

Group type: EXPERIMENTAL
Intervention: Intermittent bolus of 5 ml of 0.375% bupivacaine hourly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous infusion of 5 ml of 0.375% bupivacaine hourly
Number of subjects: 48
Study: 7829766

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg, orally, twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone challenge paradigm
Number of subjects: 0
Study: 2894164

Group type: EXPERIMENTAL
Intervention: rilmenidine 1 mg/day
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: rilmenidine 1 mg twice a day
Number of subjects: 126

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study: 29883974

Group type: EXPERIMENTAL
Intervention: intralipid/heparin infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline infusion (placebo)
Number of subjects: 20
Study: 27172830

Group type: EXPERIMENTAL
Intervention: Rotigotine (<8 mg/24 h)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 25393877

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX), Ursodeoxycholic acid (UDCA), and low-dose low molecular weight heparin (LMWH) for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 22